{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-120165","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.291871+00:00","generated_at":"2026-05-29T22:56:41.756828+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone","bullets":["ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.","ICONIC-TOTAL met primary endpoint of IGA 0/1 at week 16; results in difficult-to-treat areas.","Earned $165M milestone under amended collaboration with Janssen; payment expected Q1 2025.","Company remains eligible for up to $630M in future milestones and tiered royalties of 6-10% on net sales.","Upcoming catalysts H1 2025: Phase 2b ulcerative colitis data, PsA Phase 3 start, superiority data vs deucravacitinib."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-120165","json":"https://secwatch.observer/filing/0001104659-24-120165.json","markdown":"https://secwatch.observer/filing/0001104659-24-120165.md","text":"https://secwatch.observer/filing/0001104659-24-120165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/0001104659-24-120165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:56:41.756828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}